The approved use of Zytiga or abiraterone acetate has today been allowed to be extended by the U. S. Food and Drug Administration (FDA), a recent report has unveiled. The drug is meant to be given to patients of late-stage prostate cancer before they go for chemotherapy.

The disease affects thousands of men each year and has no proper cure till date. It has been found that metastatic or castration-resistant prostate cancer is more aggressive and needs to be addressed as early as possible. Since, the same is more treacherous for patients.

The drug Zytiga had been first approved in the year 2011 for patients who redevelop the cancer after being treated with a chemotherapy drug named docetaxel. Zytiga has the potential to cut the production of the male sex hormone i. e. testosterone.

It is being said that the drug can preserve quality of life as well as slow down the pain development. It can even curb the spread of the cancer along with improving an individual's overall health.

"Today's approval demonstrates the benefit of further evaluating a drug in an earlier disease setting and provides patients and doctors the option of using Zytiga earlier in the treatment course", director of the Office of Oncology Drug Products Richard Pazdur, M. D. was quoted as avowing.